Chapter 91

Antifungal Agents

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

Systemic Mycoses

Treatment can be difficult.

Infections often resist treatment.

Treatment may require prolonged therapy with drugs that frequently prove toxic.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

2

Major Groups of Antifungal Agents

1.

Drugs for systemic mycoses infections

2.

Drugs for superficial mycoses infections

Note: A few drugs are used for both.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

3

Antifungal Agents

1.

Systemic mycoses infections

Opportunistic

Immunocompromised host

 Candidiasis, aspergillosis, cryptococcosis, mucormycosis

Nonopportunistic

Can occur in any host

 Sporotrichosis, blastomycosis, histoplasmosis, coccidioidomycosis

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

4

Antifungal Agents

2.

Superficial mycoses infections

Candidiasis

Dermatophytes

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

5

Four Classes of Antifungal Drugs

1.

Polyene antibiotics

2.

Azoles

3.

Echinocandins

4.

Pyrimidine analogs

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

6

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

7

Amphotericin B

Broad-spectrum antifungal agent (also used against some protozoa)

Highly toxic

Infusion reaction and renal damage occur in all patients to varying degrees

Must be given IV – no oral administration

Uses

Drug of choice for most systemic mycoses

Before ampho B, systemic fungal infections were usually fatal

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

8

Amphotericin B

Mechanism of action

Binds to ergosterol (much more than cholesterol) in fungal cell membrane

Bacterial cell membranes lack sterols

Fungi damaged more than human cells

Increases the permeability

Cell leaks intracellular cations (especially potassium)

Fungistatic or fungicidal

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

9

Amphotericin B

Adverse effects

Infusion reactions

Nephrotoxicity

 Hypokalemia

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

10

Amphotericin B

Infusion reaction

Fever, chills, rigors, nausea, and headache

Caused by release of proinflammatory cytokines

Symptoms begin 1-3 hours after starting infusion and last for about 1 hour

Less intense with lipid-based ampho B formulations

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

11

Amphotericin B

Infusion reaction (cont’d)

 Mild reactions – pretreatment options

Diphenhydramine plus acetaminophen

Aspirin can help – may increase renal damage

 IV meperidine or dantrolene can be given if rigors

 occur.

Hydrocortisone can be given with caution.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

12

Amphotericin B

Nephrotoxicity

 Extent of kidney damage related to total dose administered over the full course of treatment

If total dose >4 g, residual impairment likely

Damage minimized by infusing 1 L of saline on days of treatment

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

13

Amphotericin B

Nephrotoxicity (cont’d)

Avoid other nephrotoxic drugs concurrently.

Aminoglycosides, cyclosporins

NSAIDs should also be avoided.

 Monitor serum creatinine q 3-4 days.

Reduce dosage if >3.5 mg/dL

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

14

Amphotericin B

Hypokalemia

Results from damage to the kidneys

May need potassium supplements

 Monitor serum levels

Hematologic effects

 Can cause bone marrow suppression

Anemia – monitor hematocrit

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

15

Azoles

Broad-spectrum antifungal drugs

5/14 – can be an alternative to ampho B for most systemic mycoses

Lower toxicity

Can be given orally

Disadvantage

 Inhibit P450 drug-metabolizing enzymes and can increase the levels of many other drugs

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

16

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

17

Itraconazole (Sporanox)

Azole group of antifungal agents

Lower toxicity level

Uses

 Systemic mycoses (alternative to ampho B)

Mechanisms of action

Inhibits the synthesis of ergosterol

Inhibits fungal cytochrome P450-dependent enzymes

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

18

Itraconazole (Sporanox)

Side effects (well tolerated in usual doses)

Cardiosuppression

Transient decrease in ventricular ejection fraction

Liver damage

Watch for signs of liver dysfunction

Can inhibit drug metabolizing enzymes

GI effects

Nausea, vomiting, diarrhea

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

19

Fluconazole (Diflucan)

Azole group of antifungal agents

Fungistatic

Same mechanism of action as itraconazole

Oral absorption good

 IV and oral dosage the same

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

20

Fluconazole (Diflucan)

Adverse effects

Nausea

Headache

Vomiting

Abdominal pain

Diarrhea

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

21

Voriconazole (Vfend)

Azole group of antifungal agents

Broad spectrum of fungal pathogens

Uses

Candidemia

Invasive aspergillosis

Esophageal candidiasis

Scedosporium apiospermum –resistant infections

Mechanism of action

 Suppresses synthesis of ergosterol

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

22

Voriconazole (Vfend)

Adverse effects

Hepatotoxicity

Visual disturbances, hallucinations

Fetal injury

Hypersensitivity reactions

Nausea, vomiting, and abdominal pain

Headache

Drug interactions

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

23

Ketoconazole (formerly Nizoral)

Azole group of antifungal agents

Mechanism of action

 Inhibits ergosterol

Uses: Alternative to ampho B for systemic mycoses

Less toxic and only somewhat less effective

Slower effects

More useful in suppressing chronic infections than in treating severe, acute infections

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

24

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

25

Ketoconazole (formerly Nizoral)

Adverse effects (generally well tolerated)

GI (can be reduced if given with food)

Hepatotoxicity

Rare but potentially fatal hepatic necrosis

Effect on sex hormones

Can inhibit steroid synthesis in humans

Other adverse effects

Rash, itching, dizziness, fever, chills, constipation, diarrhea, photophobia, and headache

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

26

Flucytosine (Ancobon)

Pyrimidine analog

Uses

 Serious infections of susceptible strains of

Candida and Cryptococcus neoformans

Resistance common

 Often used with ampho B

Extreme caution in patient with renal impairment or hematologic disorders

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

27

Flucytosine (Ancobon)

Adverse effects

Hematologic

Bone marrow suppression

Hepatotoxicity

Inhibits hepatic drug-metabolizing enzymes

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

28

Drugs for Superficial Mycoses

Mycoses caused by two groups of organisms

Candida species

Usually in mucous membranes and moist skin

Chronic infections may involve scalp, skin, and nails

Dermatophytic infections (eg, ringworm)

Usually confined to skin, hair, and nails

More common than Candida infections in nails

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

29

Drugs for Superficial Mycoses

Oral candidiasis (thrush)

Vulvovaginal candidiasis

 75% of women experience at least once

 Risk factors

Pregnancy, obesity, diabetes, debilitation, HIV, oral contraceptives, systemic glucocorticoids, anticancer agents, and systemic antibiotics

Onychomycosis

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

30

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

31

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

32

Drugs for Superficial Mycoses

Dermatophytic infections (eg, ringworm)

Tinea pedis (feet)

Tinea corporis (body)

Tinea cruris (groin)

Tinea capitis (scalp)

Drugs

Clotrimazole – topical

Griseofulvin – oral

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

33

Griseofulvin (Grifulvin)

Uses

Superficial mycoses

Ineffective systemic mycoses

Inhibits fungal mitosis

Adverse effects

 Transient headache

Rash

Gastrointestinal

Insomnia

Tiredness

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

34

Nystatin (Mycostatin)

Polyene antibiotic

Used only for candidiasis

Drug of choice for intestinal candidiasis

Also used for candidal infections in skin, mouth, esophagus, and vagina

Can be administered orally or topically

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.

35